Neoplasms

All Conditions

Symptoms and General Pathology

Adenocarcinoma

Neoplasm, Residual

Neoplastic Processes

A total of 50 patients with stage II-III rectal cancer who plan to receive neoadjuvant chemoradiotherapy between the ages of 18-75 years old, and these patients have no distant metastasis, normal main organ function, and can receive long-term follow-up. simultaneously, these patients are required to provide sufficient ' colonoscopy collection ' tumor tissue samples for MRD customization, and sufficient whole blood samples are required for baseline MRD detection.

Peripheral blood samples were collected for MRD detection before neoadjuvant chemoradiotherapy, during neoadjuvant chemoradiotherapy, and 3-4 weeks after radical surgery. For patients who achieved cCR after neoadjuvant therapy and adopted the W \& W strategy, the sampling time point was 3 months after the start of watching and waiting.

MRD detection

WeiWei Xiao

The purpose of this study is to study the performance of MRD monitoring in predicting the efficacy and prognosis of neoadjuvant therapy in patients with rectal cancer, and to explore the value of MRD detection in evaluating the prognosis of patients. In this prospective study, 50 patients with stage II-III rectal cancer who are planing to receive neoadjuvant chemoradiotherapy will be enrolled. The tumor tissue will be collected by colonoscopy before treatment and blood samples will be collected before treatment and during treatment.The whole blood samples will receive MRD detection. The change rate and clearance rate of MRD during treatment will be calculated, and will be associated with imaging efficacy evaluation, pathological efficacy evaluation,and prognosis, to determine the performance of MRD in predicting and judging the efficacy of neoadjuvant chemoradiotherapy and postoperative recurrence of rectal cancer.

This study is a prospective, observational study. It is expected to enroll 50 patients with newly diagnosed stage II-III rectal cancer.Before neoadjuvant chemoradiotherapy, tumor tissue will be collected by colonoscopy biopsy for WES and customized panel design, and peripheral blood samples will be collected for baseline MRD detection ( MRD1 ) and during neoadjuvant concurrent chemoradiotherapy ( MRD2-6 ) .Peripheral blood sample will be collected 3-4 weeks after radical surgery ( MRD7 ). For patients who achieved cCR after the end of neoadjuvant therapy and adopted the W \& W ( watch and wait ) strategy, the sampling time point was 3 months after the start of watching and waiting ( MRD7 ).

The samples including two kinds :1.We will collect tumor tissue samples for WES detection and customized panel.2. We will collect peripheral blood samples for MRD detection.

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Based on Circulating Tumor DNA-minimal Residual Disease Technology : A Prospective, Observational Study

The area under the ROC curve ( AUC ) of MRD

LRFS differences in patients with MRD clearance / decrease / increase

DMFS differences in patients with MRD clearance / decrease / increase

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology	NCT05969938	Rectal Adenocar... Circulating Tum... Minimal Residua... Neoadjuvant Che...	MRD detection	18 Years - 75 Years	Sun Yat-sen University
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology	NCT05969938	Rectal Adenocar... Circulating Tum... Minimal Residua... Neoadjuvant Che...	MRD detection	18 Years - 75 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for mrd detection